Agreement will give access to millions at risk for severe allergic reaction to new pain-free delivery method for epinephrine and will help in efforts to gain regulatory approval for ARS-1 (known as NeffyTM in the U.S.) around the world SAN DIEGO SEPTEMBER 22, 2020—ARS Pharmaceuticals (ARS) announced that it has...
ARS Pharmaceuticals Announces New Patent on ARS-1 (epinephrine nasal spray)
Patent approval covers fast-acting decreased dosage level for intranasal administration for type 1 allergic reaction. SAN DIEGO (July 13, 2020) – ARS Pharmaceuticals today announced that on June 16, 2020, the United States Patent and Trademark Office issued a second key patent for ARS-1, a low dose intranasal epinephrine nasal...
New Data From NeffyTM (ARS-1) Studies Profiled by AAAAI
According to data ARS Pharmaceuticals originally planned to present at the 2020 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) before its cancellation due to the situation with coronavirus disease 2019 (COVID-19), Neffy 1 mg has the potential to be the first intranasal epinephrine spray product...
ARS Pharmaceuticals to Present New Data from Neffy™ (ARS-1) Studies at AAAAI 2020 Annual Meeting
First presentation of findings from EPI03, EPI04 and EPI07 studies that examine the pharmacokinetics and pharmacodynamics of single and repeat administration of epinephrine after intranasal, intramuscular and subcutaneous administration Additional analyses measure the effects of active seasonal allergic rhinitis symptoms on the absorption of intranasal epinephrine administered as Neffy™, and...
ARS Pharmaceuticals Announces the Appointment of Two New Board Members
Expansion of Board of Directors Adds Commercialization and Financial Expertise, Further Augments Clinical and Scientific Acumen of Medical and Scientific Advisory Board SAN DIEGO – June 18, 2019 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions...